Gala­pa­gos, Ab­b­Vie glimpse ear­ly progress in search of a cys­tic fi­bro­sis triple to ri­val Ver­tex

Ab­b­Vie $AB­BV and its part­ner Gala­pa­gos $GLPG are pleased with some of the ear­ly da­ta they’re see­ing for one piece of their triple drug puz­zle for cys­tic fi­bro­sis. And they’re plan­ning to give Ver­tex a run for its mon­ey on this front.

In a small study in­volv­ing 26 pa­tients with the G551D mu­ta­tion in CFTR, a dose-es­ca­lat­ing reg­i­men of the CFTR po­ten­tia­tor GLPG1837 pro­duced a sta­tis­ti­cal­ly sig­nif­i­cant drop in sweat chlo­ride con­cen­tra­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER